In a press release, the Federal Joint Committee (G-BA) has announced that it has awarded Gilead’s Trodelvy (sacituzumab govitecan) its highest additional benefit rating. The drug was judged to offer an indication of major additional benefit in adult patients with advanced stage (ie metastatic or where the tumour cannot be surgically removed) triple-negative breast cancer who have received at least two other therapies. The G-BA concludes that the drug “increases survival time, improves quality of life and causes fewer side-effects” compared to standard chemotherapy.
The G-BA’s report notes, “overall, for sacituzumab govitecan, a major improvement in the therapy-relevant benefit compared to the appropriate comparator therapy, especially against the background of the diseases severity of triple-negative breast cancer and the unfavourable prognosis of patients who are also already in a late line of therapy in the present area”.
- www.g-ba.de, “Beschluss: Arzneimittel-Richtlinie/Anlage XII: Sacituzumab Govitecan (Mammakarzinom, triple-negativ, mindestens 2 Vortherapien)”, 19th May 2022